Previous 10 | Next 10 |
The buzz is rising around psychedelics investments — with so much attention starting to bubble up, what do new investors need to know before making stock picks? Psychedelics opportunities are popping up more and more in the public markets as bigger companies get ready to capi...
COMPASS Pathways is a business that is trying to treat a serious form of depression by using psilocybin, which is known for its psychoactive effects. COMPASS is looking to treat treatment-resistant depression (TRD), which has 80-90% relapse rate and affects 100 million people worldwid...
LONDON, June 03, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its CO...
With psychedelics, mental health care may never be the same. All as some of the nation’s “top universities are racing to set up psychedelic research centers, and investors are pouring millions of dollars into a pack of start-ups. States and cities across the country are beginn...
COMPASS Pathways (NASDAQ: CMPS) is a psychedelic company that is pursuing the use of psilocybin, the active ingredient in "magic mushrooms," for treatment-resistant depression (TRD). The phase 2 trial is ongoing. In this therapy, a person takes the drug in a controlled environment w...
Psychedelics have been long vilified, and are still illegal. Yet there may be situations where these narcotics are actually helpful to people. Studies have suggested that both MDMA (street name, "ecstasy") and psilocybin ("magic mushrooms") can help people who suffer from post-traumatic str...
Is there about to be a psychedelic drug boom in mental health treatment? In May researchers released data from a phase 3 trial that used MDMA (street name: ecstasy) along with talk therapy to treat people who have post-traumatic stress disorder (PTSD). And COMPASS Pathways (NASDAQ: CM...
Palm Beach, FL – May 25, 2021 – Recently, the use of psychedelics is evolving for the treatment of a variety of mental illnesses, including anxiety, depression, post-traumatic stress disorder and other related uses. Some psychedelic drugs are extracted from plants or mushrooms...
A bill that would legalize possession of psychedelic medications will be voted on by the California Senate after clearing a procedural hurdle, Marijuana Moment reports.Sponsored by Sen. Scott Wiener (Dem.), SB519 would legalize personal possession and use of psychedelic medications such as LS...
Healthcare companies are continuously looking for new treatment options for patients. One in particular, COMPASS Pathways (CMPS), is focused on using psilocybin therapy treat depression. The stock has generated a lot of interest, but is down 25% for the year. Is it time to buy? Read more to f...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...